Pharmaceuticals, Biotechnology and Life Sciences
– Olorinab investigated in three doses, 10 mg, 25 mg, and 50 mg, for abdominal pain associated with IBS-C & IBS-D
– Trial did not meet primary endpoint in broad study population
– Moderate to severe pain population at 50 mg showed statistically…
Fiscal Year 2021 Total Revenues of $1,465.1M, up 33% Year-over-year;
Q4 Total Revenues of $396.8M, up 27% Year-over-year;
Fiscal Year 2021 Subscription Services Revenues of $1,179.5M, up 32% Year-over-year;
Q4 Subscription Services Revenues of $322…
– Olorinab investigated in three doses, 10 mg, 25 mg, and 50 mg, for abdominal pain associated with IBS-C & IBS-D
– Trial did not meet primary endpoint in broad study population
– Moderate to severe pain population at 50 mg showed statistically…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Five Prime Therapeutics, Inc. (NASDAQ: FPRX), will report its fourth quarter and full year 2020 operational and financial results on Wednesday, March 10, 2021 after the U.S. financial markets close. Five Pr…
Two-year results further illustrate the effectiveness and sustainability of Virta’s intervention in reversing a variety of metabolic conditions
SAN FRANCISCO–(BUSINESS WIRE)–Today Virta Health, the type 2 diabetes reversal leader, announced the publ…
Two-year results further illustrate the effectiveness and sustainability of Virta’s intervention in reversing a variety of metabolic conditions
SAN FRANCISCO–(BUSINESS WIRE)–Today Virta Health, the type 2 diabetes reversal leader, announced the publ…
DUBLIN–(BUSINESS WIRE)–The “Biologic API Contract Manufacturer Quality Benchmarking (6th Edition)” report has been added to ResearchAndMarkets.com’s offering.
This Biologic API Contract Manufacturing Quality Benchmarking (6th Edition) report brings …
DUBLIN–(BUSINESS WIRE)–The “Biologic API Contract Manufacturer Quality Benchmarking (6th Edition)” report has been added to ResearchAndMarkets.com’s offering.
This Biologic API Contract Manufacturing Quality Benchmarking (6th Edition) report brings …
MUMBAI, India & REYKJAVIK, Iceland–(BUSINESS WIRE)–Gulf FZ LCC (“Cipla Gulf’), subsidiary of Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” and biopharmaceutical company Alvotech today announced that they are expanding their partne…
Epizyme’s Next EPIsode: Vision for Rewriting Oncology Treatment with Epigenetics Showcased New Five-Year Corporate Strategy
Preliminary Safety and Activity Data from Ongoing Clinical Trials for TAZVERIK® Combinations in Follicular Lymphoma and Pro…